Original language | English |
---|---|
Article number | 1190867 |
Journal | Frontiers in cellular and infection microbiology |
Volume | 13 |
DOIs | |
Publication status | Published - 2023 |
Keywords
- HIV-1
- HIV-1 latency
- HIV-1 latency reversal
- HIV-1 persistence
- HIV-1 reservoir
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Frontiers in cellular and infection microbiology, Vol. 13, 1190867, 2023.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - Editorial
T2 - The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
AU - Pasternak, Alexander O.
AU - Rohr, Olivier
AU - van Lint, Carine
AU - Kula-Pacurar, Anna
N1 - Funding Information: AOP acknowledges funding from the Dutch Medical Research Council (ZonMw), grant no. 09120011910035. CVL and OR acknowledge funding from the Belgian National Fund for Scientific Research (F.R.S-FNRS, Belgium); the French INSERM agency “ANRS/Maladies infectieuses émergentes”; the “Télévie” program of the F.R.S.-FNRS; ViiV Healthcare; the “Fondation Roi Baudouin”; the Internationale Brachet Stiftung (IBS); the Walloon Region (“Fonds de Maturation”); The “Amis des Instituts Pasteur à Bruxelles”, asbl.; the University of Brussels (ULB - Action de Recherche Concertée (ARC) grant); the NEAT (European AIDS Treatment Network) program; the University of Brussels (Action de Recherche Concertée ULB grant); the Marie Skodowska Curie COFUND action; and the European Union’s Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015. CVL is “Directrice de Recherches” of the F.R.S-FNRS. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC) (Faculty of Medicine, ULB). Funding Information: AOP acknowledges funding from the Dutch Medical Research Council (ZonMw), grant no. 09120011910035. CVL and OR acknowledge funding from the Belgian National Fund for Scientific Research (F.R.S-FNRS, Belgium); the French INSERM agency “ANRS/Maladies infectieuses émergentes”; the “Télévie” program of the F.R.S.-FNRS; ViiV Healthcare; the “Fondation Roi Baudouin”; the Internationale Brachet Stiftung (IBS); the Walloon Region (“Fonds de Maturation”); The “Amis des Instituts Pasteur à Bruxelles”, asbl.; the University of Brussels (ULB - Action de Recherche Concertée (ARC) grant); the NEAT (European AIDS Treatment Network) program; the University of Brussels (Action de Recherche Concertée ULB grant); the Marie Skodowska Curie COFUND action; and the European Union’s Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015. CVL is “Directrice de Recherches” of the F.R.S-FNRS. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC) (Faculty of Medicine, ULB).
PY - 2023
Y1 - 2023
KW - HIV-1
KW - HIV-1 latency
KW - HIV-1 latency reversal
KW - HIV-1 persistence
KW - HIV-1 reservoir
UR - http://www.scopus.com/inward/record.url?scp=85152978208&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fcimb.2023.1190867
DO - https://doi.org/10.3389/fcimb.2023.1190867
M3 - Editorial
C2 - 37077527
SN - 2235-2988
VL - 13
JO - Frontiers in cellular and infection microbiology
JF - Frontiers in cellular and infection microbiology
M1 - 1190867
ER -